Increasing Prevalence Of Diabetes Fuels Growth In The Gastroparesis Drugs Market: An Emerging Driver Transforming The Gastroparesis Drugs Market Landscape

The Gastroparesis Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Projected Growth of the Gastroparesis Drugs Market?
The gastroparesis drugs market has grown strongly in recent years. It will rise from $5.39 billion in 2024 to $5.73 billion in 2025, at a CAGR of 6.3%. The growth is driven by factors such as the side effects of existing treatments and ongoing gastrointestinal motility research.

The gastroparesis drugs market is expected to see significant growth, projected to reach $7.2 billion by 2029 with a CAGR of 5.9%. This growth is driven by the increasing prevalence of diabetes, an aging population, rising awareness and diagnosis rates, higher healare spending, and government and private funding. Key trends include advancements in gastroenterology, improved diagnostic tools, technological innovations, increased research funding, and collaborative research efforts.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15812

What Are the Different Gastroparesis Drugs Market Segments?
The gastroparesis drugs market covered in this report is segmented -

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs
2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes
3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types
4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration
5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:
1) Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme s
2) Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

What Are the Primary Drivers Shaping the Gastroparesis Drugs Market?
The growing prevalence of diabetes is expected to propel the gastroparesis drugs market. Diabetes is a long-term condition marked by elevated blood sugar levels due to insulin-related issues. Rising diabetes rates are tied to sedentary lifestyles, poor diets, urbanization, aging populations, genetic factors, and obesity. Gastroparesis drugs help alleviate symptoms like nausea and delayed gastric emptying, common among diabetic patients, thereby enhancing gastrointestinal health and life quality. For instance, in March 2024, the UK's Office for Health Improvement & Disparities stated that between March 2022 and March 2023, the percentage of type 1 diabetes patients receiving all eight care processes rose by 22%, and type 2 diabetes by 21%. Target HbA1c achievement reached a record 37.9%, according to the National Diabetes Audit. As a result, the growing diabetes burden is contributing to the expansion of the gastroparesis drugs market.

Which Companies Are Leading in the Gastroparesis Drugs Market?
Major companies operating in the gastroparesis drugs market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Inc., Teva Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Evoke Pharma Inc., Cadila Pharmaceuticals, Cipla Ltd., Neurogastrx Inc., Ipca Laboratories Ltd., ANI Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., Rhythm Pharmaceuticals Inc., Processa Pharmaceuticals Inc., Aclipse Therapeutics LLC, ETX Pharma Inc.

What Trends Are Driving Growth in The Gastroparesis Drugs Market?
Leading players in the gastroparesis drugs industry are concentrating on the launch of groundbreaking medicines like Gimoti (metoclopramide) nasal spray to secure a competitive advantage. This drug is utilized to manage gastroparesis symptoms in adults by accelerating gastric emptying through enhanced gastrointestinal mobility. Unlike other treatments, it doesn't pass through the digestive tract and is instead directly assimilated into the bloodstream via the nasal lining. As an example, in April 2022, Evoke Pharma Inc., a pharmaceutical company based in the United States, proclaimed the U.S. Food and Drug Administration (FDA) gave exclusivity for their new drug, GIMOTI (metoclopramide) nasal spray. With the protection afforded by the Hatch-Waxman Act, this exclusivity will shield the product from generic competitors for three years from its original approval, giving Evoke sole rights to its marketing.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

What Are the Top Revenue-Generating Geographies in the Gastroparesis Drugs Market?
North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Gastroparesis Drugs Market?
2. What is the CAGR expected in the Gastroparesis Drugs Market?
3. What Are the Key Innovations Transforming the Gastroparesis Drugs Industry?
4. Which Region Is Leading the Gastroparesis Drugs Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.